Jan J. Molenaar

This paper introduces a microscopy-based method to measure tumour-specific viability in neuroblastoma co-cultures and patient samples, enabling more accurate drug response assessment.

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

The paper identifies extracellular vesicles as immunosuppressive factors in neuroblastoma by profiling secretomes and showing their ability to suppress T cell activation.

The paper shows that γδ T cells, not β T cells, are the main anti-tumoral immune cells in pediatric neuroblastoma after chemotherapy.

The paper evaluates how the functional avidity of anti-B7H3 CAR-T constructs relates to their ability to trigger effector function against tumors with varying antigen density.

This study integrates immunohistochemistry and single-cell RNA sequencing data to characterize the immune landscape of pediatric brain and solid tumors, revealing distinct immune microenvironment features across tumor types.

This study identifies MIF as a key immunosuppressive factor in neuroblastoma that inhibits CAR T-cell efficacy, showing that blocking MIF enhances T-cell activation and therapeutic potential.

The paper evaluates deconvolution methods for bulk RNA-Seq using scnRNA-Seq data, identifies biases, and introduces SQUID, a method that outperforms others in predicting cell mixtures and identifying cancer subclones.

This paper develops a method to detect tumor-specific gene fusions in pediatric cancer by integrating RNA-seq and WGS, identifying 165 high-confidence fusions and their structural variants.